ELANE and COVID-19: Neutrophil activation plays a pivotal role in this process.In light of these mechanisms, Sahebnasagh and colleagues [20] have suggested that sivelestat, a neutrophil elastase inhibitor, holds promise as a therapeutic option for managing ALI/ARDS in COVID-19.